Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook

PARIS and CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) --  NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today reported an operational update and financial results for the third quarter of 2025 along with an outlook for clinical updates from studies sponsored by Nanobiotix or The University of Texas MD Anderson...

Soft Tissue Sarcoma Market Analysis Report 2025-2035, Profiles of Novartis, Nanobiotix, Adaptimmune, and Ipsen Pharma

The global soft tissue sarcoma market is poised for substantial growth from 2024 to 2035, driven by the rising prevalence of this rare, aggressive cancer affecting connective tissues. Key growth factors include advancements in targeted therapies, immunotherapies, and innovative surgical techniques. Enhanced diagnosis and treatment options, supported by personalized medicine and genetic profiling, further boost this market. North America holds a significant market share due to its advanced health...

NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth

PARIS and CAMBRIDGE, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that it has entered into a royalty-based financing agreement with HealthCare Royalty (“HCRx”), providing up to $71 million in non-dilutive capital and establishing the financial foundation for...

Nanobiotix S.A. überzeugt mit mehreren positiven Studienergebnissen — Aktie vor Ausbruch aus Base!

Nanobiotix S.A. ist ein spekulatives aber vielversprechenderes Biotechnologie-Unternehmen aus Frankreich. Es hat sich auf den Einsatz von Nanotechnologie bei Krebsbehandlungen spezialisiert. NBTXR3 ist...

Nanobiotix: Erste Erfolge im Kampf gegen therapieresistenten Krebs dank Nanotechnologie

Das französische Unternehmen weist bei seinem Kursverlauf spannende Parallelen zum gestern vorgestellten Medizintechnikspezialisten ClearPoint Neuro auf. Auch Nanobiotix befand sich in den letzten Jahren...

Nanobiotix stock jumps on positive esophageal cancer treatment data By Investing.com

Nanobiotix stock jumps on positive esophageal cancer treatment data

Nanobiotix: Todays Data Readout For Radiation Therapy Enhances Bull Case

Nanobiotix S.A. (NBTX) Q4 2024 Earnings Call Transcript

NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025

Conference call and webcast scheduled for Thursday, April 3, 2025, at 8:00 am EDT / 2:00 pm CEST Conference call and webcast scheduled for Thursday, April 3, 2025, at 8:00 am EDT / 2:00 pm CEST

NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer

PARIS and CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the completion of the dose escalation and dose expansion parts of a Phase 1 study evaluating radiotherapy(“RT”)-activated NBTXR3 (JNJ-1900) for patients with locally advanced ...

NANOBIOTIX to Participate in Multiple Investor Conferences in November

~ Guggenheim’s Inaugural Healthcare Innovation Conference, Nov 11-13 ~

NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) --  NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will host a virtual KOL (Key Opinion Leader) event Tuesday June 18, 2024 at 9:00-10:30AM EDT / 3:00-4:30PM CEST.

Nanobiotix S.A. (NBTX) Q1 2024 Earnings Call Transcript

Nanobiotix S.A. (NBTX) Q4 2023 Earnings Call Transcript

Nanobiotix to Present at Upcoming Investor Conferences in March

PARIS and CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in fireside chats at the upcoming Guggenheim Healthy Altitudes Summit and the Leerink Partners Global Biopharma Conference. Please see below for details on each event.